PATENT CLAIM ANALYSIS

Application Number: 16031357
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "275000"]

Abstract:
The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Claim (Index 3):
The pharmaceutically acceptable salt of  claim 2 , wherein the salt is a hydrochloric acid salt.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 95.0
- Lexical Diversity: 1.73333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15799661', '15301815', '15519484', '15030245', '13451574']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7287482572006113
- 35 USC 102 Novelty (BERT): 0.4718132324174904
- Combined Prediction Score: 0.7030547547222993
- Mean Citation Score: 193.758324
- Max Citation Score: 223.69833
- Similarity Product: 221.0916653353536

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test